PTC | NG | HP | P | P1 | P2 | P3 | |
---|---|---|---|---|---|---|---|
n | 132 | 48 | 63 | ||||
Age [year] | 49[22 ~ 80] | 52[29 ~ 71] | 47[26 ~ 74] | 0.06 | |||
Gender | 0.16 | ||||||
Male | 25 | 6 | 17 | ||||
Female | 107 | 42 | 46 | ||||
T | |||||||
T1 + T2 | 130 | ||||||
T3 + T4 | 2 | ||||||
N | |||||||
N0 | 83 | ||||||
N1a + N1b | 49 | ||||||
M | |||||||
M0 | 131 | ||||||
M1 | 1 | ||||||
Clinical stage | |||||||
I | 122 | ||||||
II | 10 | ||||||
Laboratory data | |||||||
T3[nmol/L] | 1.18 [1.06,1.28] | 1.23[1.12,1.31] | 1.21 [1.12,1.31] | 0.23 | |||
T4[nmol/L] | 8.20 [7.20,9.10] | 8.40 [7.15,9.00] | 8.00 [7.00,8.50] | 0.22 | |||
FT3[pmol/L] | 3.36 ± 0.41 | 3.39 ± 0.35 | 3.22 ± 0.36 | 0.04* | 0.03* | 0.03* | 0.61 |
FT4[pmol/L] | 1.32 ± 0.19 | 1.34 ± 0.17 | 1.32 ± 0.15 | 0.69 | 0.92 | 0.44 | 0.43 |
TSH [μIU/mL] | 1.55 [1.07,2.09] | 1.64[0.99,2.80] | 1.81[1.15,2.56] | 0.24 | |||
TGAb [IU/mL] | 23.5[15.0,74.5] | 21.0 [15.0,29.8] | 16.0[15.0,28.0] | 0.00* | 0.00* | 0.36 | 0.36 |
TPO [IU/mL] | 34.0[28.0,61.0] | 28.0[28.0,38.7] | 38.0[28.0,55.0] | 0.08 | |||
CD3+ PD-1+ (%) | 11.5 ± 4.7 | 5.9 ± 2.1 | 8.6 ± 4.5 | 0.00* | 0.00* | 0.00* | 0.00* |
CD3+CD4+PD-1+ (%) | 7.9 ± 3.2 | 4.3 ± 1.8 | 6.43 ± 2.7 | 0.00* | 0.00* | 0.00* | 0.00* |
CD3+CD8+PD-1+ (%) | 5.1 [2.3,6.0] | 2.8 [1.7,3.3] | 4.7[2.7,5.8] | 0.00* | 0.75 | 0.00* | 0.00* |